These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

802 related articles for article (PubMed ID: 24314876)

  • 1. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa.
    Leslie KS; Tripathi SV; Nguyen TV; Pauli M; Rosenblum MD
    J Am Acad Dermatol; 2014 Feb; 70(2):243-51. PubMed ID: 24314876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa.
    Sotiriou E; Goussi C; Lallas A; Chovarda E; Apalla Z; Lazaridou E; Ioannides D
    J Drugs Dermatol; 2012 May; 11(5 Suppl):s15-20. PubMed ID: 22644772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of Anakinra in a Case of Severe Hidradenitis Suppurativa.
    Russo V; Alikhan A
    J Drugs Dermatol; 2016 Jun; 15(6):772-4. PubMed ID: 27272089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
    Kimball AB; Kerdel F; Adams D; Mrowietz U; Gelfand JM; Gniadecki R; Prens EP; Schlessinger J; Zouboulis CC; van der Zee HH; Rosenfeld M; Mulani P; Gu Y; Paulson S; Okun M; Jemec GB
    Ann Intern Med; 2012 Dec; 157(12):846-55. PubMed ID: 23247938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa.
    Gulliver WP; Jemec GB; Baker KA
    J Eur Acad Dermatol Venereol; 2012 Jul; 26(7):911-4. PubMed ID: 21605174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients.
    Fardet L; Dupuy A; Kerob D; Levy A; Allez M; Begon E; Bachelez H; Morel P; Lebbé C
    J Am Acad Dermatol; 2007 Apr; 56(4):624-8. PubMed ID: 17240478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients.
    Gener G; Canoui-Poitrine F; Revuz JE; Faye O; Poli F; Gabison G; Pouget F; Viallette C; Wolkenstein P; Bastuji-Garin S
    Dermatology; 2009; 219(2):148-54. PubMed ID: 19590173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hidradenitis suppurativa with etanercept injection.
    Adams DR; Yankura JA; Fogelberg AC; Anderson BE
    Arch Dermatol; 2010 May; 146(5):501-4. PubMed ID: 20479297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
    Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
    Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa.
    Amano M; Grant A; Kerdel FA
    Int J Dermatol; 2010 Aug; 49(8):950-5. PubMed ID: 21128923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial.
    Tzanetakou V; Kanni T; Giatrakou S; Katoulis A; Papadavid E; Netea MG; Dinarello CA; van der Meer JWM; Rigopoulos D; Giamarellos-Bourboulis EJ
    JAMA Dermatol; 2016 Jan; 152(1):52-59. PubMed ID: 26579854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
    Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
    Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
    Blanco R; Martínez-Taboada VM; Villa I; González-Vela MC; Fernández-Llaca H; Agudo M; González-López MA
    Arch Dermatol; 2009 May; 145(5):580-4. PubMed ID: 19451504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study.
    Kerdel FR; Azevedo FA; Kerdel Don C; Don FA; Fabbrocini G; Kerdel FA
    J Drugs Dermatol; 2019 Feb; 18(2):170-176. PubMed ID: 30811140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab for the treatment of hidradenitis suppurativa.
    Fernández-Vozmediano JM; Armario-Hita JC
    Dermatology; 2007; 215(1):41-4. PubMed ID: 17587838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.
    Miller I; Lynggaard CD; Lophaven S; Zachariae C; Dufour DN; Jemec GB
    Br J Dermatol; 2011 Aug; 165(2):391-8. PubMed ID: 21457202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial.
    Alavi A; Prens EP; Kimball AB; Frew JW; Krueger JG; Mukhopadhyay S; Gao H; Ranganathan U; Ivanoff NB; Hernandez Daly AC; Zouboulis CC
    Br J Dermatol; 2024 Sep; 191(4):508-518. PubMed ID: 38576350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
    Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
    J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etanercept: effective in the management of hidradenitis suppurativa.
    Cusack C; Buckley C
    Br J Dermatol; 2006 Apr; 154(4):726-9. PubMed ID: 16536817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa.
    Boer J; Jemec GB
    Clin Exp Dermatol; 2010 Jan; 35(1):36-40. PubMed ID: 19549239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.